CCRL2 and tuberculosis: In this study, we show that Mtb infection increases the expression of CCRL2 in vitro and in vivo (lung-derived DCs, AMs and neutrophils) and targeting CCRL2 with an antibody-drug conjugate (ADC) potentiates the bactericidal activity of RHZE in a mouse TB model, suggesting that this approach may be a promising adjunctive TB therapeutic tool.